Werewolf Therapeutics Inc
HOWL1.226USD
+0.066+5.68%
交易中 （美東）報價延遲15分鐘
54.95M總市值
虧損本益比TTM
關於 Werewolf Therapeutics Inc 公司
Werewolf Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司致力於開發旨在刺激人體免疫系統治療癌症的療法。該公司正在利用其 PREDATOR 平臺設計刺激適應性和先天性免疫的條件性激活分子，旨在解決傳統促炎免疫療法的侷限性。其 INDUKINE 分子旨在在外周組織中保持無活性，但在腫瘤微環境中選擇性激活。其候選產品 WTX-124 和 WTX-330 是系統遞送的、條件性激活的白細胞介素 2 (IL-2) 和 IL-12 INDUKINE 分子，用於治療實體瘤。WTX-124 正在作爲單一療法和與派姆單抗聯合用於多種實體瘤類型進行開發。WTX-330 正在作爲轉移性實體瘤和非霍奇金淋巴瘤的單一藥物進行開發。其產品線還包括JZP898和WTX-712。
公司簡介
公司代碼HOWL
公司名稱Werewolf Therapeutics Inc
上市日期Apr 30, 2021
CEODr. Daniel J. (Dan) Hicklin, Ph.D.
員工數量46
證券類型Ordinary Share
年結日Apr 30
公司地址200 Talcott Avenue
城市WATERTOWN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02472
電話16179520555
網址https://werewolftx.com/
公司代碼HOWL
上市日期Apr 30, 2021
CEODr. Daniel J. (Dan) Hicklin, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Director
Director
--
--
Dr. Chulani Karunatilake, Ph.D.
Dr. Chulani Karunatilake, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Michael A. (Mike) Sherman
Mr. Michael A. (Mike) Sherman
Independent Director
Independent Director
--
--
Dr. Luke Evnin, Ph.D.
Dr. Luke Evnin, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Randi Isaacs, M.D.
Dr. Randi Isaacs, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Director
Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月14日 週三
更新時間: 5月14日 週三
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
14.89%
MPM Capital Inc.
9.60%
PFM Health Sciences, LP
5.59%
MPM BioImpact LLC
5.37%
BofA Global Research (US)
4.69%
Other
59.87%
持股股東
持股股東
佔比
RA Capital Management, LP
14.89%
MPM Capital Inc.
9.60%
PFM Health Sciences, LP
5.59%
MPM BioImpact LLC
5.37%
BofA Global Research (US)
4.69%
Other
59.87%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
19.93%
Venture Capital
14.89%
Hedge Fund
12.83%
Investment Advisor
9.66%
Research Firm
5.33%
Corporation
4.56%
Individual Investor
1.51%
Bank and Trust
0.08%
Family Office
0.02%
Other
31.19%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
157
30.87M
68.80%
-5.72M
2025Q1
159
30.37M
68.02%
-6.24M
2024Q4
157
31.11M
69.81%
-7.22M
2024Q3
161
35.12M
80.23%
-3.46M
2024Q2
148
35.04M
80.49%
-1.98M
2024Q1
150
35.07M
81.79%
+2.03M
2023Q4
134
30.53M
84.54%
+2.78M
2023Q3
139
30.67M
86.21%
+2.11M
2023Q2
142
30.83M
86.75%
+2.42M
2023Q1
141
30.79M
87.31%
+3.80M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
6.68M
14.89%
+536.43K
+8.73%
May 14, 2025
MPM Capital Inc.
4.31M
9.6%
--
--
Apr 14, 2025
PFM Health Sciences, LP
2.51M
5.59%
-398.94K
-13.73%
Mar 31, 2025
MPM BioImpact LLC
2.41M
5.37%
+20.80K
+0.87%
Mar 31, 2025
BofA Global Research (US)
2.10M
4.69%
+24.27K
+1.17%
Mar 31, 2025
Arkin Bio Ventures LP
2.05M
4.56%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
1.51M
3.36%
+88.47K
+6.23%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.48M
3.3%
-29.02K
-1.92%
Mar 31, 2025
Rubric Capital Management LP
1.33M
2.97%
--
--
Mar 31, 2025
Millennium Management LLC
784.62K
1.75%
+188.33K
+31.58%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
DFA Dimensional US Core Equity Market ETF
0%
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
DFA Dimensional US Core Equity Market ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
